Dihydrofolate Reductase Targeting in Tuberculosis Treatment

Dihydrofolate reductase (DHFR) plays a central role in the folate pathway of Mycobacterium tuberculosis by catalysing the reduction of dihydrofolate to tetrahydrofolate, a cofactor essential for DNA synthesis and repair. Inhibition of DHFR disrupts nucleotide biosynthesis, halting bacterial replication. Historic antitubercular agents such as para-aminosalicylic acid (PAS) are now understood to act as prodrugs that, upon metabolic activation, yield antimetabolites targeting DHFR. Despite decades of clinical use, rising resistance and suboptimal efficacy of existing antifolates demand new approaches. Recent efforts combine biochemical, structural and chemical strategies to enhance potency, selectivity and synergy. These include co-administration of sequential pathway inhibitors, disruption of competing metabolic routes and design of dual-target compounds that engage DHFR alongside other folate enzymes. Advances in high-throughput screening, molecular modelling and in vivo validation are accelerating the discovery of next-generation DHFR inhibitors with the potential to shorten therapy and overcome drug-resistant strains. The global burden of tuberculosis underscores the importance of such innovations for public health and the development of combination regimens tailored to both drug-sensitive and drug-resistant infections.

Research from Nature Portfolio

Studies have redefined the mechanism of the classic trimethoprim–sulfamethoxazole combination, revealing a bidirectional potentiation rather than simple sequential blockade. Inhibition of DHFR by trimethoprim not only starves the cell of tetrahydrofolate but also impairs synthesis of early folate precursors, magnifying the effect of sulfamethoxazole. This metabolic feedback loop explains the exceptional synergy and suggests new opportunities to exploit mutual potentiation in antifolate combinations.

Investigations into intrinsic antifolate resistance have highlighted the role of p-aminobenzoic acid (PABA) biosynthesis. Genetic disruption of the PABA pathway in M. tuberculosis dramatically sensitises bacteria to DHFR-directed drugs and PAS, lowering minimum inhibitory concentrations by orders of magnitude. Chemical inhibitors of PABA production restore the activity of underutilised antifolate agents, demonstrating a viable strategy to potentiate existing drugs.

Dihydrofolate Reductase Targeting in Tuberculosis Treatment publication trend

The graph below shows the total number of articles in dihydrofolate reductase targeting in tuberculosis treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Dihydrofolate reductase (DHFR): An enzyme that reduces dihydrofolate to tetrahydrofolate, enabling thymidine and purine synthesis.

Folate pathway: A series of enzymatic reactions producing tetrahydrofolate cofactors necessary for nucleotide and amino acid biosynthesis.

Antifolate: A class of compounds that inhibit enzymes within the folate pathway, thereby blocking DNA synthesis.

Prodrug: An inactive compound metabolised in the organism into an active therapeutic agent.

Synergy: A pharmacological interaction where combined agents produce an effect greater than the sum of their individual effects.

References

1. para-Aminosalicylic Acid Is a Prodrug Targeting Dihydrofolate Reductase in Mycobacterium tuberculosis ♦. Journal of Biological Chemistry (2013).
2. Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole. Nature Communications (2018).
3. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates. Scientific Reports (2016).
4. Dual-Target Mycobacterium tuberculosis Inhibition: Insights into the Molecular Mechanism of Antifolate Drugs. International Journal of Molecular Sciences (2023).
5. Competition between H4PteGlu and H2PtePAS Confers para-Aminosalicylic Acid Resistance in Mycobacterium tuberculosis. Antibiotics (2023).